Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Cervical Heterogenity Imaging Study

Washington University School of Medicine25 enrolled

Overview

Rationale: Diagnostic procedures, such as positron emission tomography (PET) using fluorodeoxyglucose (FDG), may help determine response to standard cancer therapy in patients with cervical cancer The purpose of this study is to evaluate the change in cervical tumor heterogenity as measured by FDG-PET/CT imaging.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Cervical Cancer

Interventions

Positron Emission TomographyPROCEDURE

FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Biopsy-proven cervical cancer. (FIGO stage-Ib2-IVa) 2. Age ≥ 18 3. Able to receive chemoradiation therapy with Cisplatin. 4. Non-pregnant status in women of childbearing potential. 5. No other active cancer at the time of diagnosis of cervical cancer Patients cannot have received treatment for any malignancy, with the exception of non-melanoma skin cancer, in the past 5 years. 6. Patients with distant metastatic disease are eligible provided the estimated survival of the patient is at least 1 year. 7. Scheduled to undergo or have already undergone FDG-PET/CT imaging for clinical staging of cervical cancer at Barnes-Jewish Hospital Clinical PET Facility on a Biograph 40 PET/CT scanner 8. Able to give informed consent Exclusion Criteria: 1. Age \< 18 2. Patients with a known active malignancy other than cervical carcinoma. 3. Pregnant and breastfeeding patients. 4. Subjects whose tumors are not FDG avid on baseline standard of care FDG-PET/CT imaging

Locations (1)

Washington University at St. Louis

St Louis, Missouri, United States

Outcomes

Primary Outcomes

The overall goal of this pilot study is to evaluate the change in cervical tumor FDG heterogeneity and SUVmax during chemoradiation.

Time frame: FDG PET/CT imaging is performed at: Baseline, 2 & 4 weeks of therapy, and 3 months after completing therapy

Secondary Outcomes

To correlate changed in FDG heterogeneity and SUVmax with response to therapy.

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.